135 related articles for article (PubMed ID: 38310331)
1. Retrospective aprotinin cardiac surgical studies and their limitations: time for a prospective randomized clinical trial.
Erdoes G; Koster A; Levy JH
Eur J Cardiothorac Surg; 2024 Feb; 65(2):. PubMed ID: 38310331
[No Abstract] [Full Text] [Related]
2. Use of Aprotinin versus Tranexamic Acid in Cardiac Surgery Patients with High-Risk for Excessive Bleeding (APACHE) trial: a multicentre retrospective comparative non-randomized historical study.
Gallo E; Gaudard P; Provenchère S; Souab F; Schwab A; Bedague D; de La Barre H; de Tymowski C; Saadi L; Rozec B; Cholley B; Scherrer B; Fellahi JL; Ouattara A;
Eur J Cardiothorac Surg; 2024 Feb; 65(2):. PubMed ID: 38180872
[TBL] [Abstract][Full Text] [Related]
3. Aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery.
Bidstrup BP
Transfusion; 2006 Dec; 46(12):2208; author reply 2209-10. PubMed ID: 17176336
[No Abstract] [Full Text] [Related]
4. The risk-benefit profile of aprotinin versus tranexamic acid in cardiac surgery.
Karkouti K; Wijeysundera DN; Yau TM; McCluskey SA; Tait G; Beattie WS
Anesth Analg; 2010 Jan; 110(1):21-9. PubMed ID: 19910626
[TBL] [Abstract][Full Text] [Related]
5. Aprotinin and renal risk in cardiac surgery.
Casati V; Galli L; D'Angelo A
Transfusion; 2006 Dec; 46(12):2207; author reply 2209-10. PubMed ID: 17176335
[No Abstract] [Full Text] [Related]
6. [Hemostatic management for cardiac surgical patients in the post-aprotinin era].
Tanaka K
Masui; 2009 Mar; 58(3):288-97. PubMed ID: 19306629
[TBL] [Abstract][Full Text] [Related]
7. A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery.
Karkouti K; Beattie WS; Dattilo KM; McCluskey SA; Ghannam M; Hamdy A; Wijeysundera DN; Fedorko L; Yau TM
Transfusion; 2006 Mar; 46(3):327-38. PubMed ID: 16533273
[TBL] [Abstract][Full Text] [Related]
8. [Aprotinin in cardiac surgery: more risks than usefulness?].
Bremerich DH; Strametz R; Kirchner R; Moritz A; Zwissler B
Anaesthesist; 2006 Sep; 55(9):989-92, 994-6. PubMed ID: 16874472
[TBL] [Abstract][Full Text] [Related]
9. Tranexamic acid compared with high-dose aprotinin in primary elective heart operations: effects on perioperative bleeding and allogeneic transfusions.
Casati V; Guzzon D; Oppizzi M; Bellotti F; Franco A; Gerli C; Cossolini M; Torri G; Calori G; Benussi S; Alfieri O
J Thorac Cardiovasc Surg; 2000 Sep; 120(3):520-7. PubMed ID: 10962414
[TBL] [Abstract][Full Text] [Related]
10. Tranexamic acid and aprotinin in primary cardiac operations: an analysis of 220 cardiac surgical patients treated with tranexamic acid or aprotinin.
Dietrich W; Spannagl M; Boehm J; Hauner K; Braun S; Schuster T; Busley R
Anesth Analg; 2008 Nov; 107(5):1469-78. PubMed ID: 18931201
[TBL] [Abstract][Full Text] [Related]
11. Low dose aprotinin and low dose tranexamic acid in elective cardiac surgery with cardiopulmonary bypass.
Waldow T; Krutzsch D; Wils M; Plötze K; Matschke K
Clin Hemorheol Microcirc; 2009; 42(4):269-77. PubMed ID: 19628892
[TBL] [Abstract][Full Text] [Related]
12. Aprotinin versus tranexamic acid: the controversy continues.
Levy JH
Transfusion; 2006 Mar; 46(3):319-20. PubMed ID: 16533270
[No Abstract] [Full Text] [Related]
13. The risks associated with aprotinin use: a retrospective study of cardiac cases in Nova Scotia.
Riddell RE; Buth KJ; Sullivan JA
Can J Anaesth; 2013 Jan; 60(1):16-23. PubMed ID: 23132043
[TBL] [Abstract][Full Text] [Related]
14. A phase 2 prospective, randomized, double-blind trial comparing the effects of tranexamic acid with ecallantide on blood loss from high-risk cardiac surgery with cardiopulmonary bypass (CONSERV-2 Trial).
Bokesch PM; Szabo G; Wojdyga R; Grocott HP; Smith PK; Mazer CD; Vetticaden S; Wheeler A; Levy JH
J Thorac Cardiovasc Surg; 2012 May; 143(5):1022-9. PubMed ID: 21724197
[TBL] [Abstract][Full Text] [Related]
15. Aprotinin and microvascular thrombosis in cardiac surgery.
Ranucci M
Intensive Care Med; 2008 Jul; 34(7):1175-6. PubMed ID: 18301878
[No Abstract] [Full Text] [Related]
16. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery.
Mangano DT; Miao Y; Vuylsteke A; Tudor IC; Juneja R; Filipescu D; Hoeft A; Fontes ML; Hillel Z; Ott E; Titov T; Dietzel C; Levin J; ;
JAMA; 2007 Feb; 297(5):471-9. PubMed ID: 17284697
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of aprotinin in cardiac surgery.
Levy JH
Orthopedics; 2004 Jun; 27(6 Suppl):s659-62. PubMed ID: 15239553
[TBL] [Abstract][Full Text] [Related]
18. Aprotinin and tranexamic acid for high transfusion risk cardiac surgery.
Wong BI; McLean RF; Fremes SE; Deemar KA; Harrington EM; Christakis GT; Goldman BS
Ann Thorac Surg; 2000 Mar; 69(3):808-16. PubMed ID: 10750765
[TBL] [Abstract][Full Text] [Related]
19. A randomized, controlled trial of aprotinin in neonates undergoing open-heart surgery.
Williams GD; Ramamoorthy C; Pentcheva K; Boltz MG; Kamra K; Reddy VM
Paediatr Anaesth; 2008 Sep; 18(9):812-9. PubMed ID: 18768040
[TBL] [Abstract][Full Text] [Related]
20. Which may be effective to reduce blood loss after cardiac operations in cyanotic children: tranexamic acid, aprotinin or a combination?
Bulutcu FS; Ozbek U; Polat B; Yalçin Y; Karaci AR; Bayindir O
Paediatr Anaesth; 2005 Jan; 15(1):41-6. PubMed ID: 15649162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
